Organization Profile

You just read:

Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease

News provided by

Resverlogix Corp.

Aug 28, 2012, 08:00 ET